Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer

Yi, Kang; Zhang, Jiancheng; Sun, Peichun; Shang, Jia

doi:10.1007/s10147-012-0405-9

Cited by 31 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,27,37 In the present study, rigorous efforts to eliminate DNA from samples of RNA, as well as limiting the number of cycles for amplification of hTERT cDNA to prevent false-positive results, might have contributed to diminished sensitivity. 18,27,37 In the present study, rigorous efforts to eliminate DNA from samples of RNA, as well as limiting the number of cycles for amplification of hTERT cDNA to prevent false-positive results, might have contributed to diminished sensitivity.…”

Section: Discussionmentioning

confidence: 94%

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Moreover, the elevated concentration of circulating RNA has been shown to be closely associated with poor prognosis in esophageal cancer, breast cancer or lymphoma 17-19. The increase of circulating cell-free hTERT mRNA was demonstrated to be correlated with reduced disease-free survival and overall survival in gastric cancer patients by Kang et al 20. As to plasma mRNA of CML-derived genes, Ma et al have reported that plasma was a reliable source for monitoring BCR-ABL mRNA levels and that minimal residual disease detection from plasma was more sensitive than from cell samples.…”

Section: Discussionmentioning

confidence: 99%

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia

Narita

Saito²,

Kojima³

et al. 2012

Int. J. Med. Sci.

View full text Add to dashboard Cite

Quantification of tumor-associated mRNA extracted from blood cells/tissues containing tumor cells is used for evaluation of treatment efficacy or residual tumor cell burden in tumors including leukemia. However, this method using tumor cell-containing blood/tissue is difficult to evaluate the whole tumor cell burden in the body. In order to establish an efficient method to evaluate the whole tumor cell burden in the body, we tried to quantify tumor-associated mRNA existing in plasma/serum instead of leukemia cell-containing blood cells in patients with chronic myelogenous leukemia (CML) and compared the levels of BCR-ABL mRNA between plasma/serum and peripheral blood cells. mRNA of BCR-ABL, WT1 or GAPDH (control molecule) was detected by real-time RT-PCR using RNA extracted from plasma/serum of almost all the patients with CML. Copy numbers of BCR-ABL mRNA were significantly correlated between plasma/serum and peripheral blood cells. However, levels of BCR-ABL mRNA extracted from serum were low compared with those extracted with peripheral blood cells. The present findings suggest that although real-time RT-PCR of mRNA existing in plasma/serum could be used for evaluating the whole tumor cell burden in the body, it's required to establish an efficient method to quantify plasma/serum mRNA by nature without degrading during the procedure.

show abstract

“…Thus, it can be used as a non-invasive marker of prostate cancer to differentiate patients with locally advanced disease at molecular level. Kang [7] and March-Villalba et al [19] detected peripheral hTERT mRNA content in patients with gastric and prostate cancer, respectively. Their results showed that hTERT mRNA content in these cancer patients was higher than that in control subjects.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies have showed that detection of free RNA in peripheral blood has higher sensitivity and tissue specificity than conventional tumor biomarkers [4–6], which opens a new field in tumor diagnosis, therapeutic evaluation and prognosis assessment. In recent years, many studies have detected hTERT mRNA in peripheral blood of patients with different tumors such as prostate cancer, lung cancer and stomach cancer [4, 5, 7] and demonstrated that elevated hTERT mRNA in peripheral blood is closely related with clinicopathological parameters, treatment efficacy and other tumor biomarkers of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance

Shen

Wang

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe study was aimed to quantitatively detect mRNA levels of the catalytic subunit of telomerase (hTERT) in both peripheral blood and circulating tumor cells (CTCs) of patients with nasopharyngeal carcinoma (NPC) and explore its significance in early diagnosis and treatment of NPC.MethodshTERT mRNA levels in peripheral blood and CTCs of 33 NPC patients before and after treatment with intensity-modulated radiation therapy (IMRT) or/and chemotherapy and 24 healthy controls were measured using real-time quantitative PCR (qPCR) and their correlations to clinic pathological factors of NPC were analyzed.ResultsPeripheral hTERT mRNA content was 10.75 ± 4.29 in NPC patients and 0.95 ± 0.37 in control subjects (P < 0.05), and had a significant correlation with patients’ clinical stage, T stage, and N stage (P < 0.05). Treatment of NPC patients at stages I and II with simple IMRT significantly reduced hTERT mRNA level from 5.60 ± 2.33 to 3.43 ± 1.42 (P < 0.05) and treatment of patients at advanced stage (III and IV) with induction chemotherapy followed by IMRT significantly reduced hTERT mRNA levels from 12.68 ± 3.08 to 10.68 ± 2.48 to 3.13 ± 1.69 (P < 0.05), respectively. In addition, the study also showed that hTERT mRNA content in CTCs of NPC patients was 10.65 ± 4.28, evidently higher than that of 1.09 ± 0.40 in control subjects (P < 0.05) and hTERT mRNA level in CTCs of NPC patients was obviously correlated to patients’ clinical stage, T stage and N stage (P < 0.05). After treatment, hTERT mRNA level in CTCs of NPC patients lowered from 10.65 ± 4.28 to 5.59 ± 2.32 (P < 0.05). The correlation analysis found that hTERT mRNA level in peripheral blood and CTCs of NPC patients were highly correlated with a correlation coefficient of 0.981.ConclusionshTERT mRNA levels in peripheral blood and CTCs of NPC patients were significantly enhanced compared to that in healthy controls and highly correlated. Changes in hTERT mRNA level was closely correlated to patients’ clinical stage and T stage. Radiochemotherapy could effectively reduce hTERT mRNA level in peripheral blood and CTCs. Thus, it is possible using the joint detection of hTERT mRNA level in peripheral blood and CTCs as a new biomarker for early diagnosis, treatment efficacy and prognosis of NPC.

show abstract

Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer

Abstract: We concluded that circulating cell-free hTERT mRNA might serve as a potential and useful noninvasive tumor marker for gastric cancer.

Cited by 31 publications

References 26 publications

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia

Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance

Contact Info

Product

Resources

About